Economy AstraZeneca’s Imfinzi misses main goal of advanced lung cancer study

AstraZeneca’s Imfinzi misses main goal of advanced lung cancer study

Image result for AstraZeneca's Imfinzi misses main goal of advanced lung cancer study
AstraZeneca’s Imfinzi misses main goal of advanced lung cancer study

London-listed drugmaker AstraZeneca Plc (AZN.L) said on Wednesday its immunotherapy treatment Imfinzi did not meet the main goal of a late-stage study for advanced non-small cell lung cancer.

The treatment was not successful in extending the lives of patients whose cancer had spread to other parts of the body. The primary group in the study also had high levels of mutations in their DNA, the company said.

Previous articleItaly’s former PM Renzi says he could be prepared to work with 5-Star movement
Next articleGermany’s Scholz sees no sign Italy will trigger euro crisis